A Pharmacokinetics Study to Assess Abiraterone Acetate Capsule and Tablet Formulations in Patients With Prostate Cancer

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Cougar Biotechnology, Inc.
ClinicalTrials.gov Identifier:
NCT00600535
First received: January 14, 2008
Last updated: April 16, 2013
Last verified: April 2013
  Purpose

The purpose of this study is to evaluate the pharmacokinetics (how the drug concentrations change over time) of capsule and tablet formulations of CB7630 (abiraterone acetate) taken with and without food in patients with prostate cancer.


Condition Intervention Phase
Prostate Neoplasms
Drug: Stage 1 Group 1: abiraterone acetate
Drug: Stage 1 Group 2: abiraterone acetate
Drug: Stage 2: abiraterone acetate
Drug: Stage 3: abiraterone acetate
Drug: Stage 3: glucocorticoid
Drug: Stage 4: abiraterone acetate
Drug: Stage 4: glucocorticoid
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Pharmacokinetics Study to Assess the Oral Administration of CB7630 (Abiraterone Acetate) Capsule Formulation and Tablet Formulation in Patients With Prostate Cancer

Resource links provided by NLM:


Further study details as provided by Cougar Biotechnology, Inc.:

Primary Outcome Measures:
  • Mean plasma concentrations of abiraterone [ Time Frame: Stage 1 predose Day 1, Days 2-4, Days 8-11; Stage 2 Day 1 Cycles 4, 7, 10 ] [ Designated as safety issue: No ]
  • Maximum plasma concentrations of abiraterone [ Time Frame: Stage 1 predose Day 1, Days 2-4, Days 8-11; Stage 2 Day 1 Cycles 4, 7, 10 ] [ Designated as safety issue: No ]
  • Time to reach the maximum plasma concentration of abiraterone [ Time Frame: Stage 1 predose Day 1, Days 2-4, Days 8-11; Stage 2 Day 1 Cycles 4, 7, 10 ] [ Designated as safety issue: No ]
  • Area under the plasma-concentration-time curve from time 0 to the last quantifiable concentration of abiraterone [ Time Frame: Stage 1 predose Day 1, Days 2-4, Days 8-11; Stage 2 Day 1 Cycles 4, 7, 10 ] [ Designated as safety issue: No ]
  • Area under the plasma-concentration-time curve from time 0 to infinite time of abiraterone [ Time Frame: Stage 1 predose Day 1, Days 2-4, Days 8-11; Stage 2 Day 1 Cycles 4, 7, 10 ] [ Designated as safety issue: No ]
  • Elimination half-life of abiraterone [ Time Frame: Stage 1 predose Day 1, Days 2-4, Days 8-11; Stage 2 Day 1 Cycles 4, 7, 10 ] [ Designated as safety issue: No ]
  • Steady state trough concentration of abiraterone [ Time Frame: Stage 1 predose Day 1, Days 2-4, Days 8-11; Stage 2 Day 1 Cycles 4, 7, 10 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Number of participants affected by an adverse event [ Time Frame: Up to 30 days after the last dose of study medication ] [ Designated as safety issue: Yes ]
  • Number of patients with serum prostate specific antigen (PSA) decline according to PSA Working Group criteria [ Time Frame: Screening; Stage 1 Day 14; Stages 2-3 Day 1, Cycles 1-12; Stage 4 every 3 cycles past Cycle 12 ] [ Designated as safety issue: No ]
  • Number of patients with circulating tumor cells isolated from peripheral blood samples defined by cell counts [ Time Frame: Screening; Stage 1 Days 1 and 8; Stage 2 Day 1 Cycless 1, 4, 7, and 10; Stage 4 every 3 cycles past Cycle 12 ] [ Designated as safety issue: No ]
  • Number of patients with circulating tumor cells isolated from peripheral blood samples defined by molecular characterization [ Time Frame: Screening; Stage 2 Day 1 Cycle 1 ] [ Designated as safety issue: No ]

Enrollment: 31
Study Start Date: July 2007
Study Completion Date: March 2012
Primary Completion Date: March 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Abiraterone acetate (non-fasting) Drug: Stage 1 Group 1: abiraterone acetate
1000 mg capsules/day orally on Day 1. On Day 8, patients will crossover and receive tablet formulation at the same dose.
Drug: Stage 1 Group 2: abiraterone acetate
1000 mg tablets/day orally on Day 1. On Day 8, patients will crossover and receive capsule formulation at the same dose.
Drug: Stage 2: abiraterone acetate
1000 mg tablets/day orally for 12 cycles (28 days/cycle) according to assigned group from Stage 1.
Experimental: Abiraterone acetate (fasting) Drug: Stage 1 Group 1: abiraterone acetate
1000 mg capsules/day orally on Day 1. On Day 8, patients will crossover and receive tablet formulation at the same dose.
Drug: Stage 1 Group 2: abiraterone acetate
1000 mg tablets/day orally on Day 1. On Day 8, patients will crossover and receive capsule formulation at the same dose.
Drug: Stage 2: abiraterone acetate
1000 mg tablets/day orally for 12 cycles (28 days/cycle) according to assigned group from Stage 1.
Drug: Stage 3: abiraterone acetate
1000 mg tablets/day orally for 12 cycles (28 days/cycle).
Drug: Stage 3: glucocorticoid
prednisone/prednisolone 5 mg twice daily orally or dexamethasone 0.5 mg once daily for 12 cycles (28 days/cycle).
Drug: Stage 4: abiraterone acetate
1000 mg tablets/day orally for up to 24 cycles (28 days/cycle).
Drug: Stage 4: glucocorticoid
prednisone/prednisolone 5 mg twice daily orally or dexamethasone 0.5 mg once daily for up to 24 cycles (28 days/cycle).

Detailed Description:

This is an open-label study (identity of assigned study drug will be known) to evaluate the pharmacokinetics of abiraterone acetate in patients with prostate cancer. The study will be conducted in 4 stages: Stage 1 will measure blood levels after patients take 1 daily dose of abiraterone tablet or capsule formulations with and without food; Stage 2 will measure blood levels of single daily doses of abiraterone tablet formulation taken with or without food in parallel design until disease progression (up to 12 cycles [28 days per cycle]); Stages 3 and 4 will evaluate the safety and antitumor effects of abiraterone tablet formulation administered with a low dose glucocorticoid in a fasted state for up to 12 months for each stage. As of Protocol Amendment 4, all patients who have completed 12 cycles of abiraterone acetate treatment and continue to receive clinical benefit from such a treatment will enter Stage 4 and receive abiraterone acetate in a fasted condition with a low-dose glucocorticoid. Patients will continue in Stage 4 for an additional 24 cycles. After patients complete the last study visit, they will be followed every 3 months for disease progression and survival for up to 3 years. Serial pharmacokinetic samples will be collected during Stages 1 and 2. Efficacy and safety will be monitored throughout the study.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Men with histologically, cytologically, or biochemically confirmed adenocarcinoma of the prostate
  • On-going androgen deprivation with serum testosterone <50 ng/dL (<2.0nmol/L)
  • Serum potassium >=3.5 mmol/L
  • Eastern Cooperative Oncology Group (ECOG) Performance Status score <2 (Karnofsky Performance Status >=50%)
  • No history of adrenal insufficiency or hyperaldosteronism
  • Any acute toxicities of prior chemotherapy, radiotherapy have resolved to a NCI CTCAE (version 3.0) grade of <=1 (chemotherapy induced alopecia and grade 2 neuropathy are excluded from this consideration)
  • No radiotherapy, chemotherapy, or immunotherapy within 30 days of administration of the study drug 1 (SD1) on Day 1
  • No surgery or local prostatic intervention within 28 days of the first dose (any clinically relevant sequelae from the surgery must have resolved prior to SD1 on Day 1)
  • Agrees to protocol-defined use of effective contraception
  • Life expectancy >12 weeks

Exclusion Criteria:

  • Active or uncontrolled autoimmune disease that may require corticosteroid therapy
  • Serious or uncontrolled co-existent non-malignant disease, including active and uncontrolled infection
  • Uncontrolled hypertension
  • Protocol-defined laboratory values
  • Clinically significant heart disease as evidenced by a myocardial infarction in the past 12 months, severe or unstable angina, or New York Heart Association (NYHA) Class III or IV heart disease (patients with a history of atherosclerotic vascular disease requiring coronary or peripheral artery bypass surgery may be enrolled provided the surgery occurred at least 2 years prior to enrollment and after consultation with a cardiologist to insure that the disease is stable)
  • Other malignancy within the previous 5-years other than basal cell or squamous cell carcinomas of skin with a >30% probability of recurrence within 12 months
  • History of gastrointestinal disorders (medical disorders or extensive surgery) which may interfere with the absorption of the study medication
  • Condition or situation which, in the investigator's opinion, may put the patient at significant risk, may confound the study results, or may interfere significantly with patient's participation in the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00600535

Locations
United States, California
Los Angeles, California, United States
United Kingdom
Glasgow, United Kingdom
Sutton, United Kingdom
Sponsors and Collaborators
Cougar Biotechnology, Inc.
Investigators
Study Director: Cougar Biotechnology Clinical Trial Cougar Biotechnology, Inc.
  More Information

Additional Information:
No publications provided

Responsible Party: Cougar Biotechnology, Inc.
ClinicalTrials.gov Identifier: NCT00600535     History of Changes
Other Study ID Numbers: CR016933, COU-AA-BE
Study First Received: January 14, 2008
Last Updated: April 16, 2013
Health Authority: United States: Food and Drug Administration
United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by Cougar Biotechnology, Inc.:
Prostate neoplasms
Abiraterone acetate
CB7630
Prostate cancer
Pharmacokinetics

Additional relevant MeSH terms:
Prostatic Neoplasms
Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on September 30, 2014